Resolution 360™ ULTRA Clip

K193424 · Boston Scientific Corporation · PKL · Sep 1, 2020 · Gastroenterology, Urology

Device Facts

Record IDK193424
Device NameResolution 360™ ULTRA Clip
ApplicantBoston Scientific Corporation
Product CodePKL · Gastroenterology, Urology
Decision DateSep 1, 2020
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 876.4400
Device ClassClass 2
AttributesTherapeutic

Intended Use

The Resolution 360 ULTRA Clip is indicated for clip placement within the Gastrointestinal (GI) tract for the purpose of: 1. Endoscopic marking 2. Hemostasis for: -Mucosal/sub-mucosal defects <3cm -Bleeding ulcers -Arteries <2mm -Polyps <1.5cm in diameter -Diverticula in the colon -Prophylactic clipping to reduce the risk of delayed bleeding post lesion resection 3. Anchoring to affix jejunal feeding tubes to the wall bowel; and Anchoring to affix fully covered sophageal self-expanding metal stents to the wall of the esophagus 4. As a supplemental closure method of luminal perforations < 20 mm that can be treated conservatively

Device Story

Resolution 360 ULTRA Clip is a sterile, single-use endoscopic device for GI tract procedures. It consists of a delivery system (handle and catheter) and a deployable clip. Operated by a physician via a forward-viewing endoscope (≥2.8mm working channel), the device allows for clip rotation and repositioning (jaws open/close up to five times) before final deployment at the lesion site. The clip is used for marking, hemostasis, anchoring feeding tubes/stents, and closing small perforations. By providing mechanical closure of tissue or vessels, the device aids in managing bleeding and structural defects, potentially reducing the need for more invasive surgical interventions.

Clinical Evidence

Bench testing only. Evaluations included clip assembly, repeated open/close cycles, opening gap, retention force, opening/closing forces, scope compatibility/usability, endoscope passibility, and MR conditionality testing per FDA guidance.

Technological Characteristics

Sterile, single-use, radiopaque endoscopic clip. Delivery system: stainless steel and polyester. Clip: stainless steel capsule/arms, Cobalt Chrome yoke, styrene tension breaker. 235cm working length. 17mm clip opening. MR Conditional. Sterilized via Ethylene Oxide (ISO 11135-1, ISO 10993-7).

Indications for Use

Indicated for patients requiring endoscopic marking, hemostasis (mucosal/sub-mucosal defects <3cm, bleeding ulcers, arteries <2mm, polyps <1.5cm, colonic diverticula, prophylactic post-resection bleeding reduction), anchoring of jejunal feeding tubes or esophageal stents, and supplemental closure of luminal perforations <20mm in the GI tract.

Regulatory Classification

Identification

A hemorrhoidal ligator is a device used to cut off the blood flow to hemorrhoidal tissue by means of a ligature or band placed around the hemorrhoid.

Special Controls

*Classification.* Class II (special controls). Except for a hemostatic metal clip intended for use in the gastrointestinal tract, the device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.

Predicate Devices

Reference Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left, there is a seal with an eagle and text around it. To the right of the seal, there is the FDA logo in blue, with the words "U.S. FOOD & DRUG" stacked on top of each other, and the word "ADMINISTRATION" below them. The logo is clean and professional, and it is likely used on official FDA documents and websites. September 1, 2020 Boston Scientific Corporation Elena Hennessey Fellow, Regulatory Affairs Specialist 100 Boston Scientific Way Marlborough, MA 01752 Re: K193424 Trade/Device Name: Resolution 360™ ULTRA Clip Regulation Number: 21 CFR 876.4400 Regulation Name: Hemorrhoidal Ligator Regulatory Class: II Product Code: PKL Dated: July 31, 2020 Received: August 3, 2020 ## Dear Elena Hennessey: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for {1}------------------------------------------------ devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely. For Shanil P. Haugen, Ph.D. Assistant Director DHT3A: Division of Renal, Gastrointestinal, Obesity and Transplant Devices OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ # Indications for Use 510(k) Number (if known) K193424 Device Name Resolution 360 ULTRA Clip Indications for Use (Describe) The Resolution 360 ULTRA Clip is indicated for clip placement within the Gastrointestinal (GI) tract for the purpose of: 1. Endoscopic marking 2. Hemostasis for: -Mucosal/sub-mucosal defects <3cm -Bleeding ulcers -Arteries <2mm -Polyps <1.5cm in diameter -Diverticula in the colon -Prophylactic clipping to reduce the risk of delayed bleeding post lesion resection 3. Anchoring to affix jejunal feeding tubes to the wall bowel; and Anchoring to affix fully covered sophageal self-expanding metal stents to the wall of the esophagus 4. As a supplemental closure method of luminal perforations < 20 mm that can be treated conservatively Type of Use (Select one or both, as applicable) X | Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) #### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ K193424 Page 1 of 3 ## SECTION 5 510(K) SUMMARY #### 510(k) SUMMARY #### 1. Submitter: Boston Scientific Corporation 100 Boston Scientific Way Marlborough, MA 01752 Contact: Elena Hennessey Fellow Regulatory Affairs Specialist Tel: 508-683-4347 Date Prepared: December 9, 2019 #### 2. Proposed Device: Trade Name: Resolution 360™ ULTRA Clip Common Name: Hemostatic Metal Clip for the GI Tract Regulation Name: Hemorrhoidal Ligator Regulation Number: 876.4400 Product Code: PKL Classification: Class II ### 3. Predicate Device: ### Primary Predicate Device: Trade Name: Resolution 360™ Clip Common Name: Hemostatic Metal Clip for the GI Tract Regulation Name: Hemorrhoidal Ligator Regulation Number: 876.4400 Product Code: PKL Classification: Class II 510(k) Clearance Number: K151802 And ### Secondary Predicate Device: Trade Name: SureClip MAX Repositionable Hemostasis Clip Common Name: Hemostatic Metal Clip for the GI Tract Regulation Name: Hemorrhoidal Ligator Regulation Number: 876.4400 Product Code: PKL Classification: Class II 510(k) Clearance Number: K182556 {4}------------------------------------------------ And # Reference Device: Trade Name: Resolution™ Hemostasis Clipping Device Common Name: Hemostatic Metal Clip for the GI Tract Regulation Name: Hemorrhoidal Ligator Regulation Number: 876.4400 Product Code: PKL Classification: Class II 510(k) Clearance Number: K122660 and K142973 # 4. Device Description: The Resolution 360TM ULTRA Clip is a sterile device consisting of a pre-loaded, radiopaque, single-use, endoscopic clipping device consisting of two main components: the delivery system and the clip. The delivery system consists of a handle and delivery catheter. The delivery system is constructed using stainless steel, and polyester materials. The delivery system will allow for the device to rotate at the distal end. The Resolution 360™ ULTRA Clip delivery system is offered in a 235cm working length. The clip consists of a stainless steel capsule, and clip arms, a Cobalt Chrome Yoke, and a styrene tension breaker. The clip is deployed from the delivery system during use. The Resolution™ 360 ULTRA Clip jaws are engineered such that they can be opened and closed up to five times prior to deployment, aiding in repositioning of the clip at the lesion site. Re-opening, closing, and rotation capability may be limited by clinical circumstances and patient anatomy. There are no associated accessories included with this device. The clip jaws will be available with a 17mm clip opening. ## 5. Indications for Use: The Resolution 360 ULTRA Clip is indicated for clip placement within the gastrointestinal (GI) tract for the purpose of: - 1. Endoscopic marking - 2. Hemostasis for: - Mucosal/sub-mucosal defects < 3 cm ● - Bleeding ulcers ● - Arteries < 2 mm ● - Polyps < 1.5 cm in diameter ● - Diverticula in the colon ● - Prophylactic clipping to reduce the risk of delayed bleeding post lesion ● resection - 3. Anchoring to affix jejunal feeding tubes to the wall of the small bowel; and Anchoring to affix fully covered esophageal self-expanding metal stents to the wall of the esophagus {5}------------------------------------------------ - 4. As a supplemental closure method of luminal perforations < 20 mm that can be treated conservatively ## 6. Technological Characteristics: The proposed Resolution™ 360 ULTRA Clip has different technological characteristic compared to the primary predict Resolution 360™ Clip (K151802). However, both the proposed and the proposed and primary predicate devices can pass through forward viewing endoscopes with a working channel equal to or greater than 2.8 mm to the target position. In addition, the materials of the components used to manufacture the deployed clip components of the proposed and primary predicate are identical. The proposed Resolution 360 ULTRA Clip has identical indications for use as the primary predicate Resolution 360 Clip. The proposed device has the identical intended use and is placed using the identical methodology as the predicate devices. The proposed device will be available with a 17mm clip opening which is similar to the secondary predicate SureClip MAX Repositionable Hemostasis Clip (K182556) and functions in the same manner as the primary predicate Resolution 360 Clip (K151802). However, the proposed devices deployed clip length is slightly longer than that the predicate devices. The materials of the proposed Resolution 360 ULTRA Clip are identical to the primary predicate device Resolution 360 Clip. ## 7. Performance Data: The proposed device meets the requirements of ISO 10993 "Biological Evaluation of Medical Devices - Part 1: Evaluation and Testing", ISO 11135-1 "Sterilization of Health Care products -Ethylene Oxide - Part 1: Requirements for Development, Validation, and Routine Control of Sterilization processes for Medical Devices", and ISO 10993-7 "Biological evaluation of medical devices - Part 7: ethylene oxide sterilization residuals", The following bench tests were performed on the Resolution™ 360 ULTRA Clip: Clip Assembly Repeated Open/Close: Clip Opening Gap: Retention Force: Clip Opening Force: Clip Close Force; Scope Compatibility/Usability; and Endoscope Damage - Clip Passibility. In addition, the proposed device was evaluated for Magnetic Resonance to support MR Conditionality for the proposed device. Magnetic Resonance (MR) testing along with scientifically based rationale for clinically relevant acceptance criteria consistent with the recommendations contained in the FDA Guidance for Establishing Safety and Compatibility of Passive Implants in the Magnetic Resonance (MR) Environment (issued December11, 2014) were completed. The results from the test data and scientific rationale have determined the Resolution 360™ ULTRA Clip to be an MR Conditional device. ## 8. Conclusion: Boston Scientific Corporation has demonstrated that the proposed Resolution 360 ULTRA Clip is substantially equivalent to the currently cleared Resolution 360 Clip (K151802) and SureClip MAX Repositionable Hemostasis Clip (K182556) as the performance of the proposed device meets the requirements of its pre-defined acceptance criteria and intended use.
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%